October 17, 2007 – CMS has received FDA 510(k) clearance for Monaco, its next-generation IMRT planning platform reportedly featuring innovative biological cost functions, allowing CMS to begin distributing Monaco for clinical use in the U.S.
Monaco includes multicriterial constrained optimization, a powerful leaf sequencer and a robust Monte Carlo dose calculation algorithm. Monaco is fully integrated with CMS's Focal platform, aiming to provide seamless connectivity and integration with Focal's advanced fusion, contouring, simulation and plan review capabilities.
For more information: www.cms-euro.com
July 09, 2024 
